Merck + Co., Inc.

Other

Elizabeth Stoner

Glenn J Gormley

Joanne Waldstreicher

Keith D Kaufman

Michel A Pontari

Curtis J Nickel

Method of prevention of prostatic carcinoma with 17&bgr;-N-monosubstituted-carbamoyl-4-aza-5&agr;-androst-1-en-3-ones

The use of a COX-2 selective inhibitor for the treatment of chronic prostatitis or chronic pelvic pain syndrome is disclosed.

Method for treating chronic prostatitis or chronic pelvic pain syndrome

The instant invention involves a method of treating and/or reversing androgenic alopecia and promoting hair growth, and methods of treating acne vulgaris, seborrhea, and female hirsutism, by administering to a patient in need of such treatment a 5&agr;-reductase 2 inhibitor, such as finasteride, in a dosage amount under 5 mgs/day.

Method of treating seborrhea with 5-&agr; reductase inhibitors

17&bgr;-N-monosubstituted-carbamoyl-4-aza-5&agr;-androst-1-en-3-ones of the formula

Method of treating acne with 5-&agr; reductase inhibitors

Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5.alpha.-reductase inhibitor, e.g. a 17.beta.-substituted 4-azasteroid, a 17.beta.-substituted non-azasteroid, 17.beta.-acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an .alpha..sub.1 -adrenergic receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.

Method of synergistic treatment for benign prostatic hyperplasia

Disclosed is a new treatment for men with prostatic cancer involving combination therapy of a 5.alpha.-reductase inhibitor, i.e., a 17.beta.-substituted 4-azasteroid, a 17.beta.-substituted non-azasteroid, 17.beta.-acyl-3-carboxyandrost-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylamino-phenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an antiandrogen, i.e. flutamide. Pharmaceutical compositions useful for treatment are also disclosed.

Method of treatment for prostatic cancer

The instant invention involves a method of treating and/or reversing androgenic alopecia and promoting hair growth, and methods of treating acne vulgaris, seborrhea, and female hirsutism, by administering to a patient in need of such treatment a 5.alpha.-reductase 2 inhibitor such as finasteride, in a dosage amount under 5 mgs/day.

Method of treating androgenic alopecia with 5.alpha.-reductase inhibitors

Method of treating androgenic alopecia with 5-alpha reductase inhibitors

The instant invention involves a method of treating and/or reversing androgenic alopecia and promoting hair growth, and methods of treating acne vulgaris, seborrhea, and female hirsutism, by administering to a patient in need of such treatment a 5.alpha.-reductase 2 inhibitor, such as finasteride, in a dosage amount under 5 mgs/day.

Growing community of inventors

Westfield, NJ, United States of America

Elizabeth Stoner